MarketPulse

risk tolerance

7 articles
The Motley FoolThe Motley Fool··Anders Bylund

Beyond Market Timing: When Tactical Rebalancing Makes Strategic Sense

Portfolio rebalancing should respond to material life changes rather than calendar dates, balancing discipline benefits against tax costs and individual circumstances.
SPYVOOIVVportfolio rebalancingasset allocation
The Motley FoolThe Motley Fool··Adria Cimino

Pfizer's 6.55% Dividend Faces Growth Questions as Patent Cliffs Loom

Pfizer's 6.55% dividend yield offers attractive income but reflects patent cliff and pandemic revenue decline pressures. Strategic restructuring and Seagen acquisition signal transformation bid.
PFEVRTXVKTXCRSPbiotechdividend sustainability
The Motley FoolThe Motley Fool··Neil Patel

Berkshire's Safety vs. Lemonade's Growth: Which Insurer Suits Your Portfolio?

Berkshire Hathaway offers stability with $373B cash and 6.2-6.4% growth; Lemonade provides 53% revenue growth but unprofitable. Choice depends on risk tolerance.
BRK.ABRK.BLMNDprofitabilityartificial intelligence
The Motley FoolThe Motley Fool··Neil Patel

Ethereum vs. Solana: Which Crypto Offers Better Value in Today's Bear Market

Ethereum offers stability with $291B market cap and 3,443 developers; Solana provides growth potential with 100x faster speeds but higher risk.
SOFISHOPcryptocurrencystablecoins
The Motley FoolThe Motley Fool··Marc Guberti

Stay the Course: Why Long-Term Strategy Beats Panic in Market Downturns

Investors should maintain long-term perspective during volatile markets, avoid panic selling, and reassess risk tolerance through strategic cash reserves and diversified holdings rather than emotional decisions.
LLYmarket volatilityportfolio diversification
The Motley FoolThe Motley Fool··Prosper Junior Bakiny

Pfizer vs. Moderna: Navigating Pharma's Post-Pandemic Pivot

Moderna's 69% YTD gain reflects mRNA vaccine upside, while Pfizer's 6.3% dividend offers stability as COVID revenues fade. Choice depends on risk appetite.
MRKPFEMRNAbiotechclinical trials
The Motley FoolThe Motley Fool··Will Healy

Figma Posts Strong Growth Despite Valuation Concerns Following Post-Earnings Rally

Figma rebounds on strong 41% revenue growth and positive free cash flow, but valuation concerns persist as stock remains 80% below IPO price amid profitability questions.
ADBEFIGvaluationrevenue growth